Literature DB >> 18482616

The intrauterine growth-restricted fetus and placenta evaluation.

R Weslie Tyson1, Barton C Staat.   

Abstract

Evaluation of the placenta is extremely important in attempting to understand the pathophysiology of intrauterine growth restriction. Only with careful gross and microscopic evaluation, along with clinical pathologic correlation can the underlying cause(s) and recurrence risks be understood.

Mesh：

Year:  2008        PMID： 18482616     DOI： 10.1053/j.semperi.2008.02.005

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN： 0146-0005            Impact factor:   3.300


  5 in total

1.  Maternal use of selective serotonin reuptake inhibitors (SSRI) during pregnancy-neonatal outcomes in correlation with placental histopathology.

Authors:  Michal Levy; Michal Kovo; Hadas Miremberg; Noa Anchel; Hadas Ganer Herman; Jacob Bar; Letizia Schreiber; Eran Weiner
Journal:  J Perinatol       Date:  2020-01-27       Impact factor: 2.521

2.  Placenta: chronicle of intrauterine growth restriction.

Authors:  Jeffrey M Dicke
Journal:  F1000 Med Rep       Date:  2010-09-23

3.  Syncytin-1 modulates placental trophoblast cell proliferation by promoting G1/S transition.

Authors:  Qiang Huang; Jinping Li; Fengchao Wang; Matthew T Oliver; Tracy Tipton; Ya Gao; Shi-Wen Jiang
Journal:  Cell Signal       Date:  2013-01-16       Impact factor: 4.315

4.  Placental pathology in pregnancies complicated by fetal growth restriction: recurrence vs. new onset.

Authors:  Michal Levy; David Alberti; Michal Kovo; Letizia Schreiber; Eldar Volpert; Liron Koren; Jacob Bar; Eran Weiner
Journal:  Arch Gynecol Obstet       Date:  2020-04-24       Impact factor: 2.344

5.  Acute Histological Chorioamnionitis and Birth Weight in Pregnancies With Preterm Prelabor Rupture of Membranes: A Retrospective Cohort Study.

Authors:  Jana Matulova; Marian Kacerovsky; Helena Hornychova; Jaroslav Stranik; Jan Mls; Richard Spacek; Hana Burckova; Bo Jacobsson; Ivana Musilova
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.